http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View More Recent Stories
-
Athira Pharma Reports First Quarter 2021 Financial Results and Provides Business Highlights
-
Athira Pharma Reports First Quarter 2021 Financial Results and Provides Business Highlights
-
Athira Pharma to Participate in Panel Discussion at Sachs 4th Annual Neuroscience Innovation Forum
-
Athira Pharma to Participate in Panel Discussion at Sachs 4th Annual Neuroscience Innovation Forum
-
Athira Pharma to Host Educational Webinar on Targeting HGF/MET: A Naturally Occurring Neuronal Repair Pathway
-
Athira Pharma to Host Educational Webinar on Targeting HGF/MET: A Naturally Occurring Neuronal Repair Pathway
-
Athira Pharma Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Highlights
-
Athira Pharma Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Highlights
-
Athira Pharma to Present at Stifel’s 3rd Annual CNS Conference
-
Athira Pharma to Present at Stifel’s 3rd Annual CNS Conference
-
Athira Pharma to Participate in Panel and Corporate Presentations at Life Science Innovation Northwest Conference
-
Athira Pharma to Participate in Panel and Corporate Presentations at Life Science Innovation Northwest Conference
-
Athira Pharma Inc. (ATHA) Announces Appointment of Barbara Kosacz to its Board of Directors
-
Athira Pharma Announces Appointment of Barbara Kosacz to its Board of Directors
-
Athira Pharma Announces Appointment of Barbara Kosacz to its Board of Directors
-
Athira Pharma to Present at H.C. Wainwright & Co. Global Life Sciences Conference
-
Athira Pharma to Present at H.C. Wainwright & Co. Global Life Sciences Conference
-
Athira Pharma to Present at the 39th Annual J.P. Morgan Healthcare Conference
-
Athira Pharma to Present at the 39th Annual J.P. Morgan Healthcare Conference
-
Athira Pharma Inc. (ATHA) Names Kelly A. Romano to Board
-
Athira Pharma Announces Appointment of Kelly A. Romano to its Board of Directors
-
Athira Pharma Announces Appointment of Kelly A. Romano to its Board of Directors
-
Athira Pharma Inc. (ATHA) Secures $15M Grant from National Institute on Aging to Support ACT-AD Clinical Trial in Alzheimer’s Disease
-
Athira Pharma Awarded $15 Million Grant from National Institute on Aging to Support ACT-AD Clinical Trial in Alzheimer’s Disease
-
Athira Pharma Awarded $15 Million Grant from National Institute on Aging to Support ACT-AD Clinical Trial in Alzheimer’s Disease
-
Athira Pharma Announces Initiation of Patient Dosing for ACT-AD Clinical Trial of ATH-1017, Small Molecule HGF/MET Activator, for Treatment of Mild-to-Moderate Alzheimer’s Disease
-
Athira Pharma Announces Initiation of Patient Dosing for ACT-AD Clinical Trial of ATH-1017, Small Molecule HGF/MET Activator, for Treatment of Mild-to-Moderate Alzheimer’s Disease
-
Athira Pharma Reports Third Quarter 2020 Financial Results and Provides Business Highlights
-
Athira Pharma Reports Third Quarter 2020 Financial Results and Provides Business Highlights
-
Athira Pharma to Present at Upcoming November Investor Conferences
-
Athira Pharma to Present at Upcoming November Investor Conferences
-
Athira Pharma to Host Educational Webinar on the Predictive Nature of P300 to Determine Clinical Benefit of Alzheimer’s Disease Treatments
-
Athira Pharma to Host Educational Webinar on the Predictive Nature of P300 to Determine Clinical Benefit of Alzheimer’s Disease Treatments
-
Athira Pharma Inc. (ATHA) Begins Patient Dosing for LIFT-AD Study, a Phase 2/3 Clinical Trial to Evaluate ATH-1017
-
Athira Pharma Announces Initiation of Patient Dosing for the LIFT-AD Study, a Phase 2/3 Clinical Trial to Evaluate ATH-1017 for Treatment of Mild-to-Moderate Alzheimer's Disease
-
Athira Pharma Announces Initiation of Patient Dosing for the LIFT-AD Study, a Phase 2/3 Clinical Trial to Evaluate ATH-1017 for Treatment of Mild-to-Moderate Alzheimer's Disease
